Intralytix, Inc. has joined Harbor Launch as an affiliate member. Intralytix was founded in 1998, and their bacteriophage-based products can be found in environmental, food processing, and medical settings.
As an early Columbus Center tenant — (years before Harbor Launch existed!) — they were a tiny company with big dreams. They wanted to exploit bacteriophage (or “phage”) technology (ubiquitous viruses that destroy bacteria, but harmless to humans, animals and plants).
“In those early days, having a space in a facility like the Columbus Center gave our tiny startup an advantage. We’re excited to be engaging with the growing community at the Columbus Center and with Baltimore’s startup community” — John Woloszyn, Intralytix CEO
Intralytix was the first company to receive FDA approval of a phage-based food additive. Today, the company commercially sells phage-based cocktails protecting human food from Listeria monocytogenes, E. coli and Salmonella. The company also sells a cocktail protecting pet food from Salmonella contamination. Intralytix is in a Phase II project funded by the USDA, developing a phage-based cocktail protecting oyster larva from Vibrio.
At the end of this year, Intralytix will be conducting a human clinical study at Mt. Sinai Hospital on a phage formulation targeting inflammatory bowel disease. The company also is planning a human clinical trial at the University of Maryland targeting shigellosis.
Intralytix continues to grow. They recently closed on a $17.5M equity investment which will be used to strengthen the company’s infrastructure by enhancing their already superb R&D programs, adding high throughput robotic technologies, and expanding their state-of-the-art phage production capabilities.
We recently toured their facility and took a deeper dive into their technology. Intralytix has always been a good neighbor; we’re elated to have them officially participate in the Harbor Launch community.